Trial Outcomes & Findings for Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy (NCT NCT01872546)

Results Overview

Number of patients with a reduction in PASI score at 4 weeks

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

18 participants

Primary outcome timeframe

4 weeks

Results posted on

2026-06-24

Participant milestones
Measure	Adalimumab Adalimumab was administered subcutaneously at a dose of 80 mg at Week 0 and 40 mg every other week starting from Week 1 to Week 16.
Overall Study STARTED	18
Overall Study COMPLETED	18
Overall Study NOT COMPLETED	0

Withdrawal data not reported

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort
Measure	Adalimumab n=18 Participants Adalimumab was administered subcutaneously at a dose of 80 mg at Week 0 and 40 mg every other week starting from Week 1 to Week 16.
Age, Customized Mean age	51.67 Years n=18 Participants
Sex: Female, Male Female	3 Participants n=18 Participants
Sex: Female, Male Male	15 Participants n=18 Participants

Timeframe: 4 weeks

Number of patients with a reduction in PASI score at 4 weeks

Outcome measures
Measure	Adalimumab n=18 Participants Adalimumab was administered subcutaneously at a dose of 80 mg at Week 0 and 40 mg every other week starting from Week 1 to Week 16.
Area and Severity Index (PASI)	14 Participants

Timeframe: 4 weeks

Number of patients with a reduction in DLGI score at 4 weeks

Outcome measures
Measure	Adalimumab n=18 Participants Adalimumab was administered subcutaneously at a dose of 80 mg at Week 0 and 40 mg every other week starting from Week 1 to Week 16.
Dermatology Life Quality Index (DLQI) Scores	14 Participants

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

Université de Poitiers